Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748442 | 0.94 | EPHX2 (0.39) | EPHX2ADRB2FAAHCNR2CNR1 | |
| SCHEMBL2748417 | 0.89 | ADRB2 (0.45) | EPHX2ADRB2ADRB3 | |
| SCHEMBL2749296 | 0.86 | EPHX2 (0.53) | EPHX2ADRB2FAAHCNR2CNR1 | |
| SCHEMBL2748977 | 0.85 | ADRA1A (0.35) | EPHX2ADRB2FAAHCNR2CNR1 | |
| SCHEMBL2795664 | 0.83 | ABCB1 (0.37) | ADRB2ABCB1BCHEADRB3 | |
| SCHEMBL2748440 | 0.83 | ADRB2 (0.44) | EPHX2ADRB2FAAHCNR2BCHE | |
| SCHEMBL2747476 | 0.80 | ADRB2 (0.47) | EPHX2ADRB2FAAHCNR2CNR1 | |
| SCHEMBL2748567 | 0.80 | EPHX2 (0.42) | EPHX2ADRB2ADRB3 | |
| SCHEMBL2791901 | 0.77 | SIRT2 (0.41) | ABCB1BCHEADRB3 | |
| SCHEMBL2747685 | 0.76 | ADRB2 (0.41) | EPHX2ADRB2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178679-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors | ALMIRALL, S.A. (ES) | 2012-05-15 | — | — | US | disclosed |
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ALMIRALL, S.A. (ES) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ADRB2, ADRB1, ADRA2C | EPHX2 598/4885ADRB2 1/4885FAAH 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.